Report
Jacob Mekhael

Autolus FIRST LOOK: 3Q24 update focusses on Aucatzyl's launch in r/r adult ALL

Yesterday before US market opens, Autolus reported 3Q24 results with a cash position of $657.1m (YE23: $239.9m), sufficient to drive Aucatzyl's (obe-cel, CD19 CAR-T) launch in r/r adult ALL, and advance the company's pipeline towards pivotal autoimmune data (KBCSe 2028). The focus of the 3Q24 update was Aucatzyl's upcoming launch, and we expect the large safety differentiation vs. Tecartus to be a key factor for adoption. In parallel, we look forward to initial autoimmune data in 1Q25, which has the potential to expand Aucatzyl's commercial opportunity and bring upside to the stock. We reiterate our $11 TP and Buy rating.
Underlying
Autolus Therapeutics ADS

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Jacob Mekhael

Other Reports on these Companies
Other Reports from KBC Securities
Guy Sips ... (+5)
  • Guy Sips
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Thibault Leneeuw
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch